Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease

被引:1
|
作者
Roy, Akash [1 ]
De, Arka [2 ]
Kulkarni, Anand V. [3 ]
Jajodia, Surabhi [4 ]
Goenka, Usha [4 ]
Tewari, Awanish [1 ]
Sonthalia, Nikhil [1 ]
Goenka, Mahesh K. [1 ]
机构
[1] Apollo Multispecial Hosp, Inst Gastrosci & Liver Transplantat, Kolkata, India
[2] Post Grad Inst Med Educ & Res, Dept Hepatol, Chandigarh, India
[3] Asian Inst Gastroenterol, Dept Hepatol, Hyderabad, India
[4] Apollo Multispecial Hosp, Dept Radiol & Imaging, Kolkata, India
关键词
Non-alcoholic fatty liver disease; Liver steatosis; Alcoholic fatty liver; GAMMA-GLUTAMYL-TRANSFERASE;
D O I
10.7570/jomes23063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (AALD) at extremes as well as an overlap group termed MASLD with increased alcohol intake (MetALD). The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) was proposed to differentiate ALD from nonalcoholic fatty liver disease (NAFLD). We analysed the performance of the ANI in differentiating within the SLD spectrum. Methods: In a cross-sectional study at a tertiary care center, 202 adults (>18 years) who were prospectively diagnosed with SLD defined by magnetic resonance imaging-proton density fat fraction > 6.4% were enrolled. Alcohol consumption (AC) was recorded according to thresholds for significant AC: 140-350 g/week (or 20- 50 g/day) for females and 210-420 g/week (or 30-60 g/day) for males. The ANI was calculated, and area under the receiver operating characteristic curve (AUROC) was generated. Results: Of 202 patients (47 years [interquartile range, IQR, 38 to 55], 23.75% females, 77% obese, 42.1% with diabetes, 38.1% hypertensive, 28.7% statin use), 40.5% were ever-alcohol consumers; 120 (59%), 50 (24.7%), and 32 (15.8%) were MASLD (ANI, -3.7 [IQR, -7 to -1.6]; MetALD, - 1.45 [IQR, -2.4 to 0.28]; and AALD, 0.71 [IQR, -1.3 to 4.8], respectively; P< 0.05 for all). The AUROC of the ANI for MASLD and AALD was 0.79 (IQR, 0.72 to 0.84; cut-off < -3.5) and 0.80 (IQR, 0.74 to 0.86; cut-off > -1.49), respectively. The ANI outperformed aspartate transaminase/alanine transaminase (AST/ALT) ratio (AUROC=0.75 [IQR, 0.69 to 0.81]) and gamma glutamyl transpeptidase (GGT) (AUROC=0.74 [IQR, 0.67 to 0.80]). Addition of GGT did not improve model performance (AUCdiff=0.004; P= 0.33). Conclusion: AC is common in MASLD. The ANI distinguishes MASLD and AALD, with individual cut-offs within the intermediate zone indicating MetALD. ANI also outperforms AST/ALT ratio or GGT.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [21] Distinguishing nonalcoholic fatty liver disease from alcoholic liver disease: Is ANI enough?
    Carvalho Filho, Roberto J.
    Milani, Andre N.
    Sampaio, Juliana P.
    Schiavon, Leonardo L.
    Schiavon, Janaina N.
    Ferraz, Maria Lucia G.
    Silva, Antonio Eduardo B.
    GASTROENTEROLOGY, 2007, 132 (05) : 2076 - 2077
  • [22] Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey
    Katsutoshi Tokushige
    Hideyuki Hyogo
    Tomoaki Nakajima
    Masafumi Ono
    Takumi Kawaguchi
    Koichi Honda
    Yuichiro Eguchi
    Yuichi Nozaki
    Miwa Kawanaka
    Saiyu Tanaka
    Kento Imajo
    Yoshio Sumida
    Yoshihiro Kamada
    Hideki Fujii
    Yasuaki Suzuki
    Tomomi Kogiso
    Yoshiyasu Karino
    Kensuke Munekage
    Ryoko Kuromatsu
    Satoshi Oeda
    Mikio Yanase
    Kohjiro Mori
    Yuji Ogawa
    Yuya Seko
    Tetsuo Takehara
    Yoshito Itoh
    Atsushi Nakajima
    Kazuyuki Kanemasa
    Ken Nishino
    Naohiko Masaki
    Hirokazu Takahashi
    Masataka Seike
    Takuji Torimura
    Toshiji Saibara
    Joji Toyota
    Kazuaki Chayama
    Etsuko Hashimoto
    Journal of Gastroenterology, 2016, 51 : 586 - 596
  • [23] LONG-TERM OUTCOMES OF LIVER TRANSPLANTATION IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE VERSUS PATIENTS WITH ALCOHOLIC LIVER DISEASE
    O'Neill, Stephen
    Napetti, Sara
    Cornateanu, Sorina M.
    Sutherland, Andrew
    Wigmore, Steve
    Oniscu, Gabriel
    Adair, Anya
    TRANSPLANT INTERNATIONAL, 2017, 30 : 421 - 421
  • [24] Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
    Castera, Laurent
    Friedrich-Rust, Mireen
    Loomba, Rohit
    GASTROENTEROLOGY, 2019, 156 (05) : 1264 - +
  • [25] Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
    Paik, James M.
    Golabi, Pegah
    Biswas, Rakesh
    Alqahtani, Saleh
    Venkatesan, Chapy
    Younossi, Zobair M.
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (06) : 890 - 903
  • [26] Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?
    Softic, Samir
    Kahn, C. Ronald
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (01) : 143 - 143
  • [27] Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease
    Suzuki, Keito
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Takahashi, Yuka
    Yamazaki, Yudai
    Uchihara, Naoki
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Keitoku, Taisei
    Okada, Risa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2024, 54 (06) : 600 - 605
  • [28] Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
    Anand, Abhinav
    Singh, Amit A.
    Elhence, Anshuman
    Vaishnav, Manas
    Biswas, Sagnik
    Gunjan, Deepak
    Gamanagatti, Shivanand R.
    Nayak, Baibaswata
    Kumar, Ramesh
    Shalimar
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (02) : 362 - 371
  • [29] Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease
    Yalamanchili, Kanthi
    Saadeh, Sherif
    Klintmalm, Goeran B.
    Jennings, Linda W.
    Davis, Gary L.
    LIVER TRANSPLANTATION, 2010, 16 (04) : 431 - 439
  • [30] Distinguishing nonalcoholic fatty liver disease from alcoholic liver disease: Is ANI enough? Reply
    Dunn, Winston
    Angulo, Paul
    Sanderson, Schuyler O.
    Kamath, Patrick S.
    Shah, Vrjay
    GASTROENTEROLOGY, 2007, 132 (05) : 2077 - 2078